Basic and clinical studies of SY5555 in respiratory infections

Hiroshi Fukuhara, Jun Inadome, Tomokazu Kakazu, Hiroaki Nakamura, Hiroshi Kaneshima, Yuei Irabu, Atsushi Saito, Nobuchika Kusano, Isamu Nakasone, Fusako Hurugen, Shinko Taira, Seitetsu Hokama, Katsuyoshi Shimoji, Hajime Ohshiro, Hiroshi Yogi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We performed a basic evaluation of SY5555, a newly developed oral penem antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity The minimum inhibitory concentrations (MICs) of SY5555 against 280 strains of 12 species isolated from clinical material were measured and compared with those of the oral cephalosporins, cefaclor, cefotiam, cefixime and cefteram and the carbapenem, imipenem/cilastatin. SY5555 was more potent than the four cephalosporins against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus milleri group, Enterococcus faecalis, Enterobacter cloacae, Acinetobacter calcoaceticus and Moraxella (Branhamella) catarrhalis, and was more active than cefotiam except against Escherichia coli. But SY5555 was less potent active than imipenem/cilastatin except against S. pneumoniae, E. faecalis and Haemophilus influenzae, and was not active against Pseudomonas aeruginosa, Serratia marcescens and methicillin-resistant S. aureus. 2. Clinical efficacy SY5555 was given to 4 patients with pneumonia, 4 with chronic bronchitis and 4 with acute bronchitis, orally at 150~300 mg three times daily for 6~19 days. The clinical response was excellent in 1, good in 10 and fair in 1. No side effects were observed, but clinical laboratory tests showed slight elevation of GOT and GPT in one patient and slight elevation of GPT in another. From the above results, we consider SY5555 to be an useful antibiotic for the treatment of bacterial respiratory infections.

Original languageEnglish
Pages (from-to)406-412
Number of pages7
Publication statusPublished - 1994
Externally publishedYes


  • SY5555

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies of SY5555 in respiratory infections'. Together they form a unique fingerprint.

Cite this